Advancements in TCR / BCR repertoire profiling and other approaches for drug target and biomarker discovery

Monday, May 5 from 12:00 - 12:45 at AAI booth 523 theatre area

Overview of Cellecta Technologies will be provided by Paul Diehl, PhD, Cellecta COO

Presenter 1: Alex Chenchik, PhD, Cellecta President & Chief Scientific Officer

A practical guide for adaptive immune receptor repertoire profiling and the characterization of antigen-induced clonotypes with applications in vaccine development, autoimmunity, and cancer

Presenter 2: Andrei Gudkov, PhD, DSci Professor of Oncology, Chair, Dept of Cell Stress Biology at Roswell Park Cancer Center

Qualitative assessment of the quality of immune response by analyzing B- and T-cell clonotypes

• Immunosenescence—the age-related decline in immune function—significantly impacts healthspan by increasing susceptibility to infections, reducing vaccine responsiveness, and elevating cancer risk in the elderly.
• We discovered that systemic stimulation of TLR5, a key component of the innate immune system, using TLR5 agonists (derived from bacterial flagellin), can enhance vaccine responses in both aged mice and humans.
• B- and T-cell clonotype profiling (via Cellecta’s DriverMap™ AIR TCR-BCR platform)  and single-cell RNA sequencing revealed insights into the mechanisms by which TLR5 stimulation exerts its rejuvenating effects on immunity.